Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 4, 2009, Pages 463-470

  Kim, Jin Seok ^a   Kim, Kihyun ^b   Cheong, June Won ^a   Min, Yoo Hong ^a   Suh, Cheolwon ^c   Kim, Hawk ^d   Jo, Deog Yeon ^e   Ryoo, Hun Mo ^f   Yoon, Sung Soo ^g   Lee, Jae Hoon ^h  

^a Yonsei University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Ulsan University College of Medicine   (South Korea)

^e Chungnam National University   (South Korea)

^f Catholic University of Daegu   (South Korea)

^g Seoul National University College of Medicine   (South Korea)

^h Gachon University College of Medicine   (South Korea)

Author keywords

Autologous stem cell transplantation; Complete remission; Multiple myeloma; Overall survival; Prognostic factor

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; M PROTEIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER REGRESSION; CHEMOSENSITIVITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNET; KOREA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 61749103773     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.12.512     Document Type: Article

References (23)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
2. Brenner H., Gondos A., and Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111 (2008) 2521-2526
3. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
4. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
5. Hari P., Pasquini M.C., and Vesole D.H. Cure of multiple myeloma: more hype, less reality. Bone Marrow Transplant 37 (2006) 1-18
6. Barlogie B., Tricot G.J., van Rhee F., et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135 (2006) 158-164
7. Singhal S., Powles R., Sirohi B., et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 30 (2002) 673-679
8. Kim H., Sohn H.J., Kim S., et al. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. Biol Blood Marrow Transplant 12 (2006) 837-844
9. Mehta J., and Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 40 (2007) 1101-1114
10. Kumar S., Lacy M.Q., Dispenzieri A., et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 34 (2004) 161-167
11. Tricot G., Crowley J., Stover J., et al. Lack of prognostic implications of induction response to Total Therapy 2 (TT-2) in newly diagnosed patients with multiple myeloma (MM) for post-transplant event-free survival (EFS) and overall survival (OS) [ASH Annual Meeting abstract]. Blood 104 (2004) 936
12. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
13. Blade J., Samson D., Reece D., et al., on behalf of the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplantation), Chronic Leukaemia Working Party and the Myeloma Working Committee of the IBMTR (International Bone Marrow Transplant Registry), and ABMTR (Autologous Blood and Marrow Transplant Registry). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102 (1998) 1115-1123
14. O'Shea D., Giles C., Terpos E., et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 37 (2006) 731-737
15. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (2008) 2516-2520
16. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
17. Ludwig H., Durie B.G., Bolejack V., et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group. Blood 111 (2008) 4039-4047
18. Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethsone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
19. Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
20. Harousseau J.L., Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 91 (2006) 1498-1505
21. Harousseau J.L., Mathiot C., Attal M., et al. Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: updated results of the IFM 2005/01 trial. Blood 110 (2007) 139 (abstr 450)
22. Cavo M., Patriarca F., Tacchetti P., et al. Bortezomib-thalidomide-dexamethasone vs thalidomide-dexamethasone in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma. Blood 110 (2007) 30 (abstr 73)
23. Lacy M.Q., Gertz M.A., Dispenzieri A., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184